BMS is the S&P’s Darling as Generic Plavix Blocked, FDA Accelerates Breast Cancer Drug Review; Merger Rumors Resurface

BMS had a good day yesterday: courts upheld its patent for Plavix (a $6-billion world market) and blocked Apotex's generic version, while FDA announced that it would accelerate review of BMS's new breast cancer drug. Bloomberg aired a report on all this yesterday.  Watch the clip here. All of this has rekindled rumors of a merger, with Sanofi-Aventis, Pfizer, AstraZeneca and GSK all in the running. More on this from Bloomberg today.

Play Video

Bristol-Meyers Squibb: A Takeover Target Again?

Bloomberg-Clip - (BLOOM-Clip)

Jun. 20, 2007. 09:00 AM EST

Bristol-Meyers's Plavix is World's Third-Best Selling Drug; Potential Suitors - Sanovi-Aventis, Pfizer, AstraZeneca, GlaxoSmithKline; Plavix Court Decision Lowers Uncertainly; UBS Sees Takeout Prospects Up to $37/share; Bristol Meyers Declines to Comment